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Abstract
To develop an inducible expression system, the  
enhanced artificial nuclear receptors and target 
reporters were constructed. Artificial nuclear re -
ceptors were generated by fusing three domains, 
consisting of DNA-binding domain (DBD) of GAL4, 
ligand binding domain (LBD) of progesterone or 
estrogen receptor, and activation domain (AD) of 
VP16, sterol regulatory element binding protein  
(SREBP)-1a, or SREBP-2. The activation domain of 
SREBP-1a showed most potent transcriptional 
activity. The maximal level of target reporter gene  
expression was extremely elevated by the usage of 
ATP citrate-lyase (ACL) minimal promoter -60/+67 in  
place of artificial TATA promoter, while the SV40  
enhancer severely increased the basal transcription  
in the absence of ligand. The induction system, 
developed in the present study, was applied to cell 
therapy, resulting in successful induction of 
single-chain insulin analogue (SIA) gene expression  
to correct the hyperglycemia in diabetic animals. By  
means of subcutaneous cell therapy, the SIA gene  
expression rapidly occurred after the local topical 
application of ligand. These results suggest that our 
system represents a powerful tool for transcriptional 
regulation of target gene that can be used for diverse  
applications, ranging from basic research to gene  
therapy.
Keywords: ATP citrate (pro-S)-lyase; diabetes melli-
tus, type 1; gene therapy; insulin; receptors, estro-
gen; receptors, progesterone; sterol regulatory ele-
ment binding protein 1
Introduction
Inducible expression systems could provide invalu-
able tools for basic research to elucidate the 
functions of specific gene product in physiological 
process, as well as many diverse applications, 
including the generation of transgenic or knock-out 
animal (Gingrich and Roder, 1998), and the con-
trolled administration of gene products in gene 
therapy (Roscilli et al., 2002; Malphettes and 
Fussenegger, 2006). The ideal inducible expression 
system should have several characteristics. First, 
gene expression should be tightly controlled by the 
on/off system. Second, the gene expression should 
be enough low in basal not to develop undesired 
effects and could be induced to sufficiently high 
levels to obtain a physiological response. Third, 
regulatory inducers should be nontoxic and should 
not alter the expression of endogenous genes. 
Several inducible expression systems with the 
above characteristics have been developed. To 
develop an inducible expression system, artificial 
transcription factor or artificial nuclear receptor as 
transcription regulator, and target reporter are 
prerequisite. A number of transcription regulators 
have been generated by various means, using the 
DNA-binding domains (DBD) originated from yeast 
or prokaryote transcription factors such as GAL4 
(Marmorstein et al., 1992), LexA (Szuts and Bienz, 
2000) and TetR (Gossen and Bujard, 1992). Also, 
ligand binding domains (LBD) of several nuclear 
hormone receptors (Braselmann et al., 1993; Wang 
et al., 1994; Burcin et al., 1999), and activation 
domains (AD) derived from herpes simplex virus 
(Baim et al., 1991; Gossen and Bujard, 1992; 
Braselmann et al., 1993; Wang et al., 1994; Burcin et 
al., 1999) have been the most widely used. 
    Here, we describe an inducible expression system 
with several important improvements. Artificial nu-
clear receptors were rendered more potent and 
immunologically improved by usage of nonviral 
strong activation domains originated from human 
sterol regulatory element binding protein (SREBP) 
transcription factors, instead of viral VP16 AD. 
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Several target reporter constructs were also de-
veloped, which show different basal and induced 
levels. Using our enhanced inducible system, we 
successfully demonstrated that it works not only in 
vitro, but also in experimental mice.
Materials and Methods
Construction of artificial nuclear receptor and target 
reporter
The artificial nuclear receptor pG4-PR-VP16, pG4- 
PR-BP1a and pG4-PR-BP2 were generated from 
pFA2-Elk1 (Stratagene) by inserting the cDNA of 
progesterone receptor (PR) LBD (amino acids 
645-891) and herpesvirus VP16 activation domain 
(amino acids 411-487) or SREBP-1a activation 
domain (amino acids 1-79) or SREBP-2 activation 
domain (amino acids 1-79). SREBP-1a AD was 
obtained from pET-SREBP-1a (Moon et al., 2000) by 
BamHI/SacI digestion. SREBP-2 AD was generated 
by PCR with primer set of 5’-GGCGAATTCAGAT-
CCATGGACGACAGCGGC-3', 5'-CTGCTAGATCTG-
CTGCCACTGCTGCC-3' from pCS2 (Moon et al., 
2000), and then digested with EcoRI/BglII. VP16 AD 
was prepared from pACT (Stratagene) by digestion 
with EcoRI/BglII. First, pFA-Elk1 was digested with 
EcoRI/SacI for insertion of SREBP-1a AD or EcoRI/ 
BglII for SREBP-2 AD and VP16 AD, and ligated 
with respective AD cDNAs. Next, the Elk region was 
removed by digestion with BamHI/EcoRI and then 
replaced with LBDs of progesterone or estrogen 
receptor. PR LBD cDNA was obtained by PCR- 
amplification with primer set of 5'-AGCCAGGG-
ATCCACTTTTTCACCAGGTCAA-3', 5'-CTGGATG-
AATTCATTCAAGCAGTACAGATG-3' from human 
breast cancer cDNA. Estrogen receptor (ER) LBD 
cDNA was also generated by PCR with primer set of 
5'-CCAAGCGGATCCATGATCAAACGCTCTAAG-3', 
5'-GGATGCGAATTCACGGCTAGTGGGCGCATG-3'. 
The LBD cDNA were digested with BamHI/EcoRI 
and substituted for Elk region. To generate the target 
reporter, GAL4 responsive elements were amplified 
from pFR-luc (Stratagene) using the primer set of 
5'-AGTCGCGGCCGCGGTCGGAGTACT, 5'-AGTC-
GTCGACGGTACCAACAGTAC-3'. The PCR product 
was digested with NotI and XbaI and cloned into the 
NotI and XbaI sites of the pBluescript II SK (+) 
(Stratagene). Then, the ATP citrate-lyase (ACL) 
minimal promoter -60/+67 was inserted at XbaI and 
SmaI sites of this vector by blunt ligation. Resulting 
plasmid was cut at downstream of ACL minimal 
promoter -60/+67 with XhoI and ligated with XhoI/ 
SalI fragment isolated from pGL3-basic or pGL3- 
enhancer in proper orientation, resulting in pGA-luc 
and pGE-luc. For construction of pGA-SIA, the luci-
ferase gene was removed by HindIII/XbaI digestion 
and then single-chain insulin analogue (SIA) gene 
was inserted at EcoRV site between ACL minimal 
promoter -60/+67 and SV40 poly A signal. SIA gene 
was obtained by digestion with SalI/HindIII of 
pLPK-SIA (Lee et al., 2000) and treatment with 
Klenow enzyme.
Cell culture and transfection
NIH3T3 cells obtained from ATCC were cultured in 
Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin G 
sodium, 100 g/ml streptomycin sulfate. All cell 
culture materials were purchased from Invitrogene. 
NIH3T3 cells were plated at a density of 2 × 105 
cells/6-well dish. On the following day, transfection 
was performed with 1 g of DNA/well LipofectAMINE 
reagent (Invitrogene) according to the manufac-
turer’s instruction. After 3 h, DNA-Lipofectamine 
complex was removed and the media was replaced 
with fresh media. Twenty-four hours after transfection, 
gene expression was induced by medium change to 
1 M of RU486 or 17 -estradiol containing media. 
Two days after transfection, cells were washed with 
phosphate-buffered saline (Invitrogene) and lysed in 
200 l of reporter lysis buffer (Promega). Luciferase 
activities were measured using the Luciferase Assay 
System (Promega) and normalized with -galacto-
sidase activities to correct the transfection efficiency. 
All experiments were done in triplicate and were 
repeated at least twice. 
Animal experiments
7-week-old BALB/C male mice (Daehan Biolink, 
Korea) were used. Animals were administered 50 
mg/kg of streptozotocin (Sigma) intra-peritoneally 
(i.p). Animals were confirmed to be diabetic above 
400 mg/100 ml blood glucose level and experiments 
were performed. About 3 × 106 NIH3T3 cells in two 
100-mm dishes were transfected with 13.5 g of 
target gene and 1.5 g of artificial nuclear receptor. 
Twenty-four hours after transfection, about 1.2 × 107 
cells were harvested with trypsin and suspended in 
500 l of DMEM. The cell suspension was injected 
into subcutaneous tissue on the interscapular region, 
using 19-gauge needle. The backs of animals were 
completely shaved before the transplantations and 
we marked the region of the skin bulge by cell 
suspension after the transplantations. Two days after 
transplantation, 50 l of RU486 (4 mg/ml in ethanol) 
or 50 l of 17 -estradiol (2 mg/ml in ethanol) solution 
were topically applied by slowly dropping them on 
the marked skin covering the transplantation and 
blood glucose levels were determined in blood 
obtained through tail bleeds.
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Results
Construction of the ligand-dependent inducible gene 
expression systems 
Artificial transcription factors have similar structure 
to the nuclear hormone receptors. They are com-
posed of three functionally distinctive domains, DBD, 
LBD, and AD. We prepared two kinds of inducible 
expression systems based on LBD’s derived from 
progesterone receptor (amino acids 645-891) or 
estrogen receptor (amino acids 279-554). The LBD 
of PR used in present study is the mutated form by 
deleting C-terminal 42 amino acids. The deleted 
form of PR LBD to which progesterone cannot bind, 
can avidly interact with progesterone antagonist, 
RU486, and thus enable to generate the inducible 
system to respond only to exogenous ligand but not 
to endogenous progesterone. In order to increase 
the activation potential of artificial transcription 
factor, we examined the three activation domains 
originated from VP16 (amino acids 411-487), 
SREBP-1a (amino acids 1-79) or SREBP-2 (amino 
acids 1-79). The N-terminal acidic domain of SREBP- 
1a was well known to be potent activation domain 
interacting coactivators, such as CBP/p300 and 
ARC/DRIP (Oliner et al., 1996; Naar et al., 1998; 
Naar et al., 1999). For DNA-binding specificity, we 
used DBD of GAL4 (amino acids 1-148), which is 
well known yeast transcription factor and does not 
affect the mammalian gene expression (Carey et al., 
1989; Marmorstein et al., 1992). Artificial nuclear 
receptors were generated by joining these domains 
in order of DBD, LBD and AD from N-terminus 
(Figure 1A). In order to test the transcriptional 
Figure 1. PR LBD- and ER LBD-based inducible expression system for the control of gene expression. (A) Diagram of artificial nuclear receptor and 
target reporter constructs used in the inducible expression system. The artificial nuclear receptor consists of DBD of yeast transcriptional activator 
GAL4, LBD of progesterone or estrogen receptor, and AD of VP16 or SREBP-1a or SREBP-2, respectively. Resulting plasmids expressing these nu-
clear receptors under the control of CMV promoter were constructed, and named as pG4-PR-VP16, pG4-PR-BP1a, and pG4-PR-BP2 in PR 
LBD-based constructs, and pG4-ER-VP16, pG4-ER-BP1a, and pG4-ER-BP2 in ER LBD-based constructs. The reporter construct, pFR-Luc, has 5 
copies of GAL4 response element (17mer) at the upstream of artificial TATA box promoter followed by the luciferase gene. (B, C) NIH-3T3 cells were 
transfected with 0.6 g of pFR-luc, 0.2 g of pCMV- -gal and various amounts (0 to 200 ng) of the indicated artificial nuclear receptor. The total 
amount of transfected plasmids was adjusted to 1 g by addition of pcDNA3. Twenty-four hours after transfection, cells were either left untreated or 1 
M of RU486 (B) or 17 -estradiol (C) was added. Two days after transfection, cells were harvested and the luciferase activities were assayed. The 
reporter activities are shown as the relative luciferase activity normalized by the -galactosidase activity. Values represent the mean ± S.D of three 
independent experiments.
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activity of artificial nuclear receptors, we employed a 
reporter construct, pFR-Luc, which have minimal 
promoter consisting of 5 copies of Gal4 response 
element (17mer) and artificial TATA box, controlling 
the expression of luciferase gene (Figure 1A).
Ligand-dependent transactivation by artificial 
nuclear receptors in transient transfection assay 
We transfected CMV promoter-driven artificial nu-
clear receptor expression constructs along with the 
reporter construct pFR-Luc into NIH3T3 cells in 
order to check the availability of our inducible 
expression systems. Figure 1B and C showed the 
ligand-dependent transcriptional activity of artificial 
nuclear receptors. As shown in Figure 1B, pro-
gesterone antagonist, RU486, could induce trans-
criptional activity of pG4-PR-VP16, pG4-PR-BP1a 
and pG4-PR-BP2. When using the VP16 AD, basal 
transcriptional activity in the absence of ligand was 
about 2 times higher than other artificial receptors. 
The artificial nuclear receptors that contained ADs of 
SREBPs showed relatively small background activity 
and high inducibility. Among three artificial nuclear 
receptors, pG4-PR-BP1a was the most profitable for 
the inducible gene expression systems because it 
showed lower background activity and highest 
inducible transcriptional activity by ligand. These 
results could be also applied to ER LBD-based 
system. However ligand-dependent transcriptional 
activation of the ER LBD-based systems is much 
stronger than PR LBD-based systems. The results 
demonstrate that AD of SREBP-1a is more excellent 
than those of VP16 and SREBP-2 in points of low 
basal activity and high induction folds, leading us to 
use the artificial transcription factors containing AD 
of SREBP-1a in remaining all experiments.
    We next examined the ability of the artificial 
nuclear receptor to induce the target gene express-
ion over a range of ligand concentrations (Figure 2). 
In PR LBD-based system, ligand-dependent activa-
tion showed to be proportional to the ligand con-
centrations up to 1,000 nM, whereas in ER LBD- 
based system, reporter gene activation was mark-
edly induced from 0.1 to 1 nM and was already 
saturated at 10 nM. These results suggested that in 
PR LBD-based system, the levels of the expression 
of target gene could be controlled by the con-
centration of RU486, while ER LBD-based inducible 
factor has the characteristics of the on/off system.
Construction of target reporter constructs showing  
different expression levels
Even though the inducibility appeared to be high due 
to minimal basal expression, the induction of target 
gene expression might not reach to therapeutic 
doses. In these cases, the therapeutic doses of 
inducible system, such as DNA or modified cells, 
must be increased. Another strategy to circumvent 
these problems is to elevate the absolute amounts of 
the induced gene expression by increasing the basal 
expression to maximum level not to produce 
undesired effects. In present study, we introduced 
the ACL minimal promoter instead of artificial TATA 
promoter to increase the expressed levels by 
artificial transcription factor, resulting in construction 
of pGA-Luc (Figure 3A). And to further increase the 
basal promoter activity, the SV40 enhancer se-
quence was inserted into the downstream of the poly 
Figure 2. Transcriptional activation of the inducible expression system is dependent on RU486 or 17 -estradiol concentration. NIH-3T3 cells were 
transfected with 0.6 g of pFR-luc, 0.2 g of pCMV- gal and 100 ng of pG4-PR-BP1a (A) or pG4-ER-BP1a (B). Twenty-four hours after transfection, 
cells were treated with various concentration (0-1 M of RU486 (A) or 17 -estradiol (B)). Two days after transfection, cells were harvested and the lu-
ciferase activities were assayed. The reporter activities are shown as the relative luciferase activity normalized by the -galactosidase activity. Values 
represent the mean ± S.D of three independent experiments.
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(A) signal, resulting in pGE-Luc (Figure 3A). As 
shown in Figure 3B, pFR-luc showed highest 
ligand-dependent induction folds by pG4-PR-BP1a 
and pG4-ER-BP1a, but the levels of ligand-induced 
reporter gene expression is very low in comparison 
to those of pGA-luc. The replacement of artificial 
TATA box promoter with ACL minimal promoter 
markedly elevated the basal promoter activity to 140 
fold.  The addition of SV40 enhancer, resulting in 
pGE-Luc, further increased the basal activity up to 
1200 folds, which is 8 fold higher than the value of 
ligand-induced promoter activities of pFR-luc in PR 
LDB based-system. In the ligand-dependent induc-
tions of pGA-luc by pG4-PR-BP1a and pG4-ER-BP1a 
were 16 and 25 folds higher than those of pFR-Luc.
    In summary, pFR-Luc showed almost absence of 
basal promoter activity and highest inducibility, and 
pGE showed very high basal expression, whereas 
pGA-Luc might have moderate basal activity and 
much effective inducibility. As results, we tested the 
pGA reporter system for the application to gene 
therapy in the diabetic animals.
In vivo application of inducible gene expression  
system
To test the feasibility of our inducible expression 
system in experimental mice, we generate the target 
gene construct pGA-SIA, which was generated by 
substitution of single-chain insulin analogue (SIA) 
gene for luciferase gene in pGA-luc (Lee et al., 
2000). We chose SIA as a target gene, because SIA 
possesses biologically active insulin activity by itself 
without proteolytic process. The NIH3T3 cells were 
Figure 3. Comparison of gene expression by modified target reporter. (A) Diagram of target reporter constructs. Target reporter pGA-luc contains the 
ACL minimal promoter -60/+67, pGE-luc contains the ACL minimal promoter -60/+67 and SV40 enhancer. (B, C) NIH-3T3 cells were transfected with 
0.6 g of the indicated reporters, 0.2 g of pCMV- gal and various amounts (0 to 200 ng) of pG4-PR-BP1a (B) or pG4-ER-BP1a (C). Twenty-four 
hours after transfection, cells were either left untreated or 1 M RU486 (B) or 17 -estradiol (C) was added. Two days after transfection, cells were 
harvested and the luciferase activities were assayed. The reporter activities are shown as the relative luciferase activity normalized by the 
-galactosidase activity. Values represent the mean ± S.D of three independent experiments. Numbers above the black bars indicate the ratios of li-
gand-induced activities in comparison to basal activities in absence of ligand.
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cotransfected with the expression construct of the 
artificial nuclear receptor and the target gene 
pGA-SIA, and then followed by transplantation of the 
cells into the interscapular region of STZ-induced 
diabetic BALB/C mice, subcutaneously. After trans-
plantation, high blood glucose levels were not 
changed at all. Two days after transplantation, 50 l 
of RU486 (4 mg/ml in ethanol) or 50 l of 17 - 
estradiol (2 mg/ml in ethanol) solution were topically 
applied to the region of transplantation. The blood 
glucose levels started to decrease at 2 h and 
reached to hypoglycemic state at 5 h after ligand 
administration in both experiments of pG4-PR-BP1a 
and pG4-ER-BP1a, whereas pGA-Luc did not signi-
ficantly affected the blood glucose levels (Figure 4A 
and 4B). The hypoglycemia at 5 h could be cor-
rected within 2 h after washing out the skin with 
ethanol and administration of glucose (data not 
shown). In this experiment, we show that our induci-
ble expression system has a fast and sufficient 
induction of SIA gene to treat hyperglycemia in vivo.
Discussion
Inducible expression systems have been very useful 
tools in the gene function study, the generation of 
animal models of disease and the gene therapy. 
Several inducible expression systems have been 
used successfully to regulate transgene expression 
in cultured cells, in transgenic mice, and in mice 
injected with viral vectors (Braselmann et al., 1993; 
Wang et al., 1994; Wang et al., 1997; Burcin et al., 
1999; Wang et al., 1999; Cronin et al., 2001; Cao et 
al., 2002). Wang et al (1994) have developed PR 
LBD-based inducible expression system, which uses 
a chimeric transcription regulator, GLVP, constructed 
by fusing the ligand binding domain of the mutant 
human progesterone receptor to the yeast trans-
criptional activator GAL4 DBD and the herpes 
simplex virus protein VP16 AD. Also, Braselmann et 
al (1993) have developed ER LBD-based inducible 
expression system using a chimeric molecule, 
GAL-ER-VP16, consisting of the estrogen receptor, 
GAL4 DBD, and the VP16 AD, which induced the 
reporter gene at least 100 folds. Although the VP16 
AD was commonly used as a activation domain in 
the construction of artificial transcription factors, 
VP16 protein has a higher probability that could 
cause an immune response in human. Moreover, the 
high expression levels of the VP16 AD are known to 
have squelching effect, which can be toxic to cells. 
Therefore, to minimize possible toxicity and immu-
nogenic reactions of these inducible expression 
systems for human gene therapy, the mammalian 
transcription factor ADs has been used instead of 
VP16 AD. Brucin et al (1999) constructed the re-
gulator GLp65, which consists of the GAL4 DBD, PR 
LBD, and AD of human p65, a partner of NF- B in 
the human RelA heterodimeric transcription factor. 
As a result, the possible toxicity of this system was 
decreased. The regulator GLp65 has a similar 
potency in the induction of target gene expression in 
transient transfection when compared with GLVPc, 
which consists of the GAL4 DBD, PR LBD, and 
VP16 AD.
    The AD of human SREBP-1a, used in this ex-
periment, showed much more potency in ligand- 
Figure 4. Conditional expression of SIA gene in subcutaneously transplanted fibroblasts, which were transfected with SIA-inducible system. NIH3T3 
fibroblasts were transfected with 13.5 g of pGA-luc (open symbols) or pGA-SIA (closed symbols) and 1.5  g of pG4-PR-BP1a (A) or pG4-ER-BP1a 
(B) per a 10 cm plate. Twenty-four hours after transfection, about 1.2 × 107 cells were harvested with trypsin and suspended in 500 l of DMEM. 
The cell suspension was subcutaneously injected at interscapular region of each streptozotocin (STZ)-induced diabetic mice. Two days after trans-
plantation, 50 l of RU486 (4 mg/ml in ethanol) or 17 -estradiol (2 mg/ml in ethanol) solution were topically applied to the region of transplantation 
and blood glucose levels were determined in blood obtained through tail bleeds. Each data represents an individual mouse.
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dependent induction system, than those of VP16 or 
SREBP-2. Induction ratio of the PR LBD-based 
system was 158- to 183-fold, up to 3 times higher 
than that of previous reported system and ER 
LBD-base system was 732- to 1009-fold, 7- to 10 
times higher than that of previous reported system 
(Braselmann et al., 1993; Burcin et al., 1999). 
Because basal expression of artificial TATA box in 
pFR-luc is very low, the induced expression of target 
gene was also relatively low in spite of extremely 
high induction folds. If this reporter system were 
applied to gene therapy, the effective treatment 
would require the high copy number of target genes 
or large number of the cells containing the target 
gene. To minimizes the transduction dose of target 
gene or the numbers of the cells modified by gene 
transduction, the basal expression level of reporter 
construct should be increased to relatively high level 
to be tolerated in non-induced state. In present 
study, ACL minimal promoter -60/+67, in place of 
artificial TATA promoter, was used to increase the 
basal expression. ACL is a cytosolic enzyme that 
catalyzes the cleavage of citrate into oxaloacetate 
and acetyl-CoA (Kornacker and Ball, 1965). The 
activity of ACL is mainly regulated at transcriptional 
level in response to dietary status and insulin, like 
other lipogenic enzymes (Kim et al., 1992). ACL 
promoter activity was increased by the overex-
pression of SREBP-1a and SREBP-2. However, the 
ACL minimal promoter -60/-67 shows very low basal 
activity and did not respond to SREBPs (Moon et al., 
2000). ACL minimal promoter -60/+67 drastically 
elevated the ligand-induced expression levels, which 
were 16 and 25 folds higher than those of artificial 
TATA promoter. This increase might not only be 
derived from increased transcription, but also 
probably from increased mRNA stability and its 
translation due to 5' UTR of ACL. However, the 
addition of SV40 enhancer severely elevates the 
basal expression, which was much higher than the 
ligand-induced expression of artificial TATA pro-
moter. 
    To supply the insulin to the diabetic animals, we 
generated the fibroblasts containing inducible insulin 
analogue (SIA) expression system and transplanted 
into diabetic animals subcutaneously. Initially, we 
used the minimal TATA promoter for SIA expression, 
but the blood glucose levels were not affected at all 
after ligand treatment (data not shown), suggesting 
that the levels of ligand-dependent SIA expression 
were much less than the doses to drop blood 
glucose levels in diabetic animals. Next, we did 
same experiments using pGA-SIA containing ACL 
minimal promoter and demonstrated that our in-
ducible expression system has a fast kinetics in-
duction, which shows tight on/off control by ligand in 
vivo. Because the steroid sex hormones had the 
enormous actions in mammals, local topical appli-
cation of hormones could minimize their systemic 
action. Previously, therapeutic proteins, which were 
expressed in skin of transgenic animal, reported to 
be delivered successfully into circulation (Wang, et 
al., 1999; Cao et al., 2002). SIA protein also showed 
the rapid delivery from subcutaneous tissue into 
circulation. Topical application of steroid hormones 
onto skin could achieve rapid induction of SIA and 
enable the induced transcription of SIA gene to 
easily be terminated by washing out topical appli-
cants. In case of diabetes, the secretion of insulin 
very rapidly occurs to large extent during the short 
postprandial period. However, it is impossible to 
induce the expression for short period by systemic 
administration of steroid hormones due to their long 
half-life. If the capacity of target gene expression 
level were sufficient, topical short-time application of 
inducer might enable rapid quantitative secretion of 
insulin for short period, similar to its physiological 
secretion pattern. For these goals, we tried to 
increase absolute expression level of target gene 
induced by ligand by replacement of activation 
domain of artificial nuclear receptor and changing 
the minimal promoter of its reporter construct, and 
we show that our inducible expression system has a 
fast and sufficient induction of SIA gene to correct 
hyperglycemia in vivo.
    In conclusion, we generated the inducible ex-
pression system with several important impro-
vements. This enhanced inducible expression sys-
tem would not only be useful for analyzing the 
function of exogenous gene, but may also be 
implemented in gene therapy protocols in which a 
therapeutic gene is delivered.
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